Cargando…

Harnessing Natural Mosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design

The year 2021 marks the 40th anniversary since physicians recognized symptoms of the acquired immunodeficiency syndrome (AIDS), a disease that has since caused more than 30 million deaths worldwide. Despite the passing of four decades, there remains no licensed vaccine for the human immunodeficiency...

Descripción completa

Detalles Bibliográficos
Autores principales: Sealy, Robert E., Dayton, Barry, Finkelstein, David, Hurwitz, Julia L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151930/
https://www.ncbi.nlm.nih.gov/pubmed/34064894
http://dx.doi.org/10.3390/v13050884
_version_ 1783698499840245760
author Sealy, Robert E.
Dayton, Barry
Finkelstein, David
Hurwitz, Julia L.
author_facet Sealy, Robert E.
Dayton, Barry
Finkelstein, David
Hurwitz, Julia L.
author_sort Sealy, Robert E.
collection PubMed
description The year 2021 marks the 40th anniversary since physicians recognized symptoms of the acquired immunodeficiency syndrome (AIDS), a disease that has since caused more than 30 million deaths worldwide. Despite the passing of four decades, there remains no licensed vaccine for the human immunodeficiency virus type 1 (HIV-1), the etiologic agent of AIDS. Despite the development of outstanding anti-retroviral drugs, there are currently more than one-half million deaths each year due to AIDS. Here, we revisit a conventional vaccine strategy used for protection against variable pathogens like HIV-1, which combines an array of diverse surface antigens. The strategy uses antibody recognition patterns to categorize viruses and their surface antigens into groups. Then a leader is assigned for each group and group leaders are formulated into vaccine cocktails. The group leaders are ‘natural mosaics’, because they share one or more epitope(s) with each of the other group members. We encourage the application of this conventional approach to HIV-1 vaccine design. We suggest that the partnering of an antibody-instructed envelope cocktail with new vaccine vectors will yield a successful vaccine in the HIV-1 field.
format Online
Article
Text
id pubmed-8151930
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81519302021-05-27 Harnessing Natural Mosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design Sealy, Robert E. Dayton, Barry Finkelstein, David Hurwitz, Julia L. Viruses Communication The year 2021 marks the 40th anniversary since physicians recognized symptoms of the acquired immunodeficiency syndrome (AIDS), a disease that has since caused more than 30 million deaths worldwide. Despite the passing of four decades, there remains no licensed vaccine for the human immunodeficiency virus type 1 (HIV-1), the etiologic agent of AIDS. Despite the development of outstanding anti-retroviral drugs, there are currently more than one-half million deaths each year due to AIDS. Here, we revisit a conventional vaccine strategy used for protection against variable pathogens like HIV-1, which combines an array of diverse surface antigens. The strategy uses antibody recognition patterns to categorize viruses and their surface antigens into groups. Then a leader is assigned for each group and group leaders are formulated into vaccine cocktails. The group leaders are ‘natural mosaics’, because they share one or more epitope(s) with each of the other group members. We encourage the application of this conventional approach to HIV-1 vaccine design. We suggest that the partnering of an antibody-instructed envelope cocktail with new vaccine vectors will yield a successful vaccine in the HIV-1 field. MDPI 2021-05-11 /pmc/articles/PMC8151930/ /pubmed/34064894 http://dx.doi.org/10.3390/v13050884 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Sealy, Robert E.
Dayton, Barry
Finkelstein, David
Hurwitz, Julia L.
Harnessing Natural Mosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design
title Harnessing Natural Mosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design
title_full Harnessing Natural Mosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design
title_fullStr Harnessing Natural Mosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design
title_full_unstemmed Harnessing Natural Mosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design
title_short Harnessing Natural Mosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design
title_sort harnessing natural mosaics: antibody-instructed, multi-envelope hiv-1 vaccine design
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151930/
https://www.ncbi.nlm.nih.gov/pubmed/34064894
http://dx.doi.org/10.3390/v13050884
work_keys_str_mv AT sealyroberte harnessingnaturalmosaicsantibodyinstructedmultienvelopehiv1vaccinedesign
AT daytonbarry harnessingnaturalmosaicsantibodyinstructedmultienvelopehiv1vaccinedesign
AT finkelsteindavid harnessingnaturalmosaicsantibodyinstructedmultienvelopehiv1vaccinedesign
AT hurwitzjulial harnessingnaturalmosaicsantibodyinstructedmultienvelopehiv1vaccinedesign